Tickertape - Financial freedom begins here
- NIFTY 5025,149.850.81% 205.40
- SENSEX82,500.470.83% 689.81
- MARKET MOOD14:20
Greed
Market and sectors
See AllNIFTY 100 Largecap | 25,748.750.86% | ||
NIFTY 100 Midcap | 58,562.801.01% | ||
NIFTY 100 Smallcap | 18,744.251.12% |
NIFTY Bank | 56,715.100.42% | ||
NIFTY IT | 37,638.151.92% | ||
NIFTY Pharma | 22,223.500.66% |
NIFTY 100 Largecap | 25,748.750.86% | ||
NIFTY 100 Midcap | 58,562.801.01% | ||
NIFTY 100 Smallcap | 18,744.251.12% |
NIFTY Bank | 56,715.100.42% | ||
NIFTY IT | 37,638.151.92% | ||
NIFTY Pharma | 22,223.500.66% |
Today's stocks
STOCKSPRICECHANGE | |
![]() Hindustan Unilever LtdHINDUNILVR | ₹2,519.604.62% |
₹1,835.201.38% | |
![]() Mankind Pharma LtdMANKIND | ₹2,578.301.35% |
![]() Interglobe Aviation LtdINDIGO | ₹5,917.501.33% |
₹3,176.701.16% |
Mutual funds and ETFs
FUNDSRETURNS | |
![]() Equity • Growth | |
![]() 7.50% Equity • Growth | |
![]() 6.56% Equity • Growth | |
![]() Equity • Growth | |
![]() 5.60% Equity • Growth |
Curated screens and deals
Market and sectors
See AllNIFTY 100 Largecap | 25,748.750.86% | ||
NIFTY 100 Midcap | 58,562.801.01% | ||
NIFTY 100 Smallcap | 18,744.251.12% |
NIFTY Bank | 56,715.100.42% | ||
NIFTY IT | 37,638.151.92% | ||
NIFTY Pharma | 22,223.500.66% |
NIFTY 100 Largecap | 25,748.750.86% | ||
NIFTY 100 Midcap | 58,562.801.01% | ||
NIFTY 100 Smallcap | 18,744.251.12% |
NIFTY Bank | 56,715.100.42% | ||
NIFTY IT | 37,638.151.92% | ||
NIFTY Pharma | 22,223.500.66% |
Today's stocks
STOCKSPRICECHANGE | |
![]() Hindustan Unilever LtdHINDUNILVR | ₹2,519.604.62% |
₹1,835.201.38% | |
![]() Mankind Pharma LtdMANKIND | ₹2,578.301.35% |
![]() Interglobe Aviation LtdINDIGO | ₹5,917.501.33% |
₹3,176.701.16% |
Curated screens and deals

NEXT Medical Writing Automation, an advanced platform that combines deep medical writing expertise with generative AI (GenAI). Purpose-built by experienced medical writers, NEXT Medical Writing Automation operates within familiar environments like Microsoft Word, auto-generating compliant drafts that adapt to diverse sponsor formats and workflows. It integrates seamlessly with Regulatory Information Management (RIM) systems, maintaining traceability and consistency across documents. NEXT Medical Writing Automation combines Indegene's decades of domain knowledge with the power of its AI engine, Cortex. Sameer Lal, SVP, Enterprise Medical Solutions, Indegene, said, 'With automated scheduling, intelligent task assignments, and robust data flow integration, NEXT Medical Writing Automation helps life sciences organizations scale operations efficiently while maintaining a strong compliance backbone. As document requirements grow and scrutiny intensifies, such solutions become essential to sustaining operational excellence. We see this platform as more than automation'it's about elevating the entire practice of medical writing. Writers can now focus on strategic tasks and critical thinking, while the platform manages the heavy lift of data and formatting.' Indegene is a digital-first life sciences commercialization company that partners with biopharmaceutical, emerging biotech, and medical device companies to develop products, bring them to market, and enhance their impact throughout the product lifecycle'more effectively, efficiently, and in a modern, technology-driven manner. The company's consolidated net profit jumped 24.1% to Rs 117.60 crore on 12.3% increase in net sales to Rs 755.60 crore in Q4 FY25 over Q4 FY24. The scrip declined 1.02% to settle at Rs 564.35 on the BSE.Powered by Capital Market - Live

Kabra Extrusion Technik has revised the meeting of the Board of Directors which was scheduled to be held on 16 July 2025. The meeting will now be held on a later date.Powered by Capital Market - Live

Droneacharya Aerial Innovations has revised the meeting of the Board of Directors which was scheduled to be held on 20 June 2025. The meeting will now be held on 11 July 2025.Powered by Capital Market - Live
Mutual funds and ETFs
FUNDSRETURNS | |
![]() Equity • Growth | |
![]() 7.50% Equity • Growth | |
![]() 6.56% Equity • Growth | |
![]() Equity • Growth | |
![]() 5.60% Equity • Growth |
Money
Matters
- Assets tracked worth60,500 Cr
- Loved by60 L+ investors
- Downloads6.2M+
- Rated on Google Play4.2
